Vaccine stocks decline as Robert F. Kennedy Jr. is nominated for health department role

Stocks of major European and U.S. vaccine manufacturers have dropped following Robert F. Kennedy Jr.'s nomination to lead the Department of Health and Human Services. Kennedy is known for his anti-vaccine stance and has made false claims about vaccine safety. Concerns among FDA and NIH employees have risen due to Kennedy's critical views on mainstream medical practices. He has expressed intentions to reform federal health agencies, emphasizing transparency and evidence-based science. While some vaccine stocks fell, companies like Moderna, Pfizer, and BioNTech saw gains after reporting strong third-quarter earnings. GSK, Valneva, AstraZeneca, and others experienced declines, with GSK's stock down nearly 4%.